Acute Hepatic Porphyria Patients Asked to Take Part in Study Survey
Note: This story was updated on Feb. 2, 2021, to note that cutaneous symptoms are more common in VP and HCP than in AIP or ADP.
Participation is in the form of a survey, estimated to take about 30 minutes to complete, according to announcement on the foundation’s website.
This survey aims to better understand the emotional, mental, and physical burden that acute hepatic porphyria places on people with the disorder, as well as on family and friends. Broadly, its goal is to better understand the needs of people with porphyria, through a greater understanding of the disease, how its manifestations change over time, and the toll it takes on people.
Individual results from the survey will be kept confidential. A direct link to the survey can be found here.
The POWER study is being conducted by Kantar, an independent research agency, and is sponsored by Alnylam Pharmaceuticals. The company markets Givlaari (givosiran), an injection treatment for acute hepatic porphyria approved for adults in the U.S., and individuals ages 12 and up in the European Union.
Alnylam will use survey findings to help in efforts to increase education and awareness about porphyria among medical and healthcare professionals, as well as patients and caregivers.
There are four types of acute hepatic porphyria: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), and the rarer delta-aminolevulinic acid dehydratase deficiency porphyria (ADP).
All are characterized by impairments in the body’s ability to produce heme, a component of hemoglobin — the molecule that is used to ferry oxygen through the bloodstream — and of a cellular process that produces energy. Because of this, porphyrins (heme precursors) build up in the body, with toxic effects.
Each type is caused by distinct genetic mutations — for example, HCP is caused by mutations in the gene CPOX, whereas VP is caused by mutations in the PPOX gene. Symptoms vary among the different types as well; for example, cutaneous (skin-affecting) symptoms are more common in VP and HCP than in AIP or ADP.
In addition to the American Porphyria Foundation, the survey is being conducted with assistance from the patient advocacy groups Global Porphyria Advocacy Coalition and International Porphyria Patient Network.